National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 12769-12770 [2013-04210]
Download as PDF
Federal Register / Vol. 78, No. 37 / Monday, February 25, 2013 / Notices
Dated: February 19, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–04215 Filed 2–22–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: AIDS and Related
Research Integrated Review Group; AIDS
Immunology and Pathogenesis Study
Section.
Date: March 18, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Mayflower Park Hotel, 405 Olive
Way, Seattle, WA 98101.
Contact Person: Shiv A Prasad, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5220,
MSC 7852, Bethesda, MD 20892, 301–443–
5779, prasads@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Predictors of
Substance Use in Young Adulthood.
Date: March 18, 2013.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Anna L Riley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7759, Bethesda, MD 20892, 301–435–
2889, rileyann@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
CounterACT U54 Centers of Excellence.
Date: March 19, 2013.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Mar<15>2010
17:22 Feb 22, 2013
Jkt 229001
Place: St. Gregory Hotel, 2033 M Street,
NW., Washington, DC 20036.
Contact Person: Jonathan K Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040A,
MSC 7806, Bethesda, MD 20892, (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Oncological Sciences.
Date: March 19–20, 2013.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Inese Z Beitins, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7892, Bethesda, MD 20892, 301–435–
1034, beitinsi@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
CounterAct U01 Cooperative Agreements.
Date: March 19, 2013.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street
NW., Washington, DC 20036.
Contact Person: Jonathan K Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040A,
MSC 7806, Bethesda, MD 20892, (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA DA14–
001: U.S.-RUSSIA Bilateral Collaborative
Research Partnerships (CRP) on the
Prevention and Treatment of HIV/AIDS and
Co-Morbidities (R21).
Date: March 19–20, 2013.
Time: 7:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street
NW., Washington, DC 20036.
Contact Person: Hilary D Sigmon, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, (301) 594–
6377, sigmonh@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 15, 2013.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–04204 Filed 2–22–13; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
12769
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Vaccine
Research Center Board of Scientific
Counselors, NIAID.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Allergy and
Infectious Diseases, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
In the interest of security, NIH has
instituted stringent procedures for
entrance onto the NIH campus. All
visitor vehicles, including taxicabs,
hotel, and airport shuttles will be
inspected before being allowed on
campus. Visitors will be asked to show
one form of identification (for example,
a government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
Name of Committee: Vaccine Research
Center Board of Scientific Counselors, NIAID.
Date: April 29–30, 2013.
Closed: 8:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 40, Room 1201/1203, 40 Center
Drive, Bethesda, MD 20892.
Contact Person: John R Mascola, MD,
Deputy Director, Vaccine Research Center,
NIAID, NIH, 40 Convent Drive, Bethesda, MD
20892, (301) 496–1852, jmascola@nih.gov.
Name of Committee: Vaccine Research
Center Board of Scientific Counselors, NIAID.
Date: April 29, 2013.
Closed: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate personal
qualifications and performances, and
competence of individual investigators.
Place: National Institutes of Health,
Building 40, Room 1201/1203, 40 Center
Drive, Bethesda, MD 20892.
Contact Person: John R. Mascola, MD,
Deputy Director, Vaccine Research Center,
NIAID, NIH, 40 Convent Drive, Bethesda, MD
20892, (301) 496–1852, jmascola@nih.gov.
Name of Committee: Vaccine Research
Center Board of Scientific Counselors, NIAID.
Date: April 30, 2013.
E:\FR\FM\25FEN1.SGM
25FEN1
12770
Federal Register / Vol. 78, No. 37 / Monday, February 25, 2013 / Notices
Closed: 8:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate personal
qualifications and performances, and
competence of individual investigators.
Place: National Institutes of Health,
Building 40, Room 1201/1203, 40 Center
Drive, Bethesda, MD 20892, (301) 496–1852.
Contact Person: John R. Mascola, MD,
Deputy Director, Vaccine Research Center,
NIAID, NIH, 40 Convent Drive, Bethesda, MD
20892, (301) 496–1852, jmascola@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 19, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–04210 Filed 2–22–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
SAMHSA/CSAP program
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: National Outcome Measures
(NOMs) for Substance Abuse
Prevention—(OMB No. 0930–0230)—
Revision
This is a revision to the previously
OMB approved instrument for the
Center for Substance Abuse Prevention’s
(CSAP) National Outcome Measures for
Substance Abuse Prevention (NOMs).
Data are collected from SAMHSA/CSAP
grants and contracts where community
and participant outcomes are assessed.
The analysis of these data helps
determine whether progress is being
made in achieving SAMHSA/CSAP’s
mission. The primary purpose of this
system is to promote the use among
SAMHSA/CSAP grantees and
contractors of common National
Outcome Measures recommended by
SAMHSA/CSAP with significant input
from panels of experts and state
representatives.
Approval of this information
collection will allow SAMHSA to
continue to meet Government
Number of
grantees
Number of
respondents
Performance and Results Modernization
Act of 2010 (GPRAMA) reporting
requirements that quantify the effects
and accomplishments of its
discretionary grant programs which are
consistent with OMB guidance, and
address goals and objectives outlined in
the Office of National Drug Control
Policy’s Performance Measures of
Effectiveness.
Note that the only changes is the
deletion of one question per instrument,
the deletion of prior Fiscal Years, and
the PPC program which was not funded.
The question being deleted is Has the
Service Member experienced any of the
following (select all that apply)
(a) Deployed in support of combat
operations (e.g. Iraq or Afghanistan)
(b) Was physically injured during
combat operations
(c) Developed combat stress symptoms/
difficulties adjusting following
deployment, including PTSD,
depression, or suicidal thoughts
(d) Died or was killed
The total annual burden estimate is
shown below:
Responses
per
respondent
Number of
responses
Hours/
response
Total hours
FY 13
Science/Services:
Fetal Alcohol .....................................
Capacity:
HIV ....................................................
SPF SIG ............................................
SPF SIG/Community Level * ............
SPF SIG/Program Level * ................
PFS ...................................................
PFS/Community Level * ...................
Annual Average .........................
23
4,800
14,400
3
0.4
5,760
122
35
........................
........................
37
........................
217
31,964
........................
29,925
9,100
........................
37,000
112,889
95,892
........................
29,925
27,300
........................
37,000
204,517
3
0
1
3
0
1
........................
0.4
........................
0.4
0.4
........................
0.4
........................
38,357
........................
11,970
10,920
........................
14,800
81,807
mstockstill on DSK4VPTVN1PROD with NOTICES
* The Strategic Prevention Framework State Incentive Grant (SPF SIG) and Partnerships for Success (PFS) have a three level evaluation: The
Grantee, Community and Program Level. The Grantee level data will be pre-populated by SAMHSA. The use of the Community Level instrument
is optional as they relate to targeted interventions implemented during the reporting period. At the program level, items will be selected in line
with direct services implemented.
Written comments and
recommendations concerning the
proposed information collection should
be sent by March 27, 2013 to the
SAMHSA Desk Officer at the Office of
Information and Regulatory Affairs,
Office of Management and Budget
(OMB). To ensure timely receipt of
comments, and to avoid potential delays
in OMB’s receipt and processing of mail
sent through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
VerDate Mar<15>2010
17:22 Feb 22, 2013
Jkt 229001
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via email,
commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
PO 00000
Frm 00057
Fmt 4703
Sfmt 9990
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
Summer King,
Statistician.
[FR Doc. 2013–04270 Filed 2–22–13; 8:45 am]
BILLING CODE 4162–20–P
E:\FR\FM\25FEN1.SGM
25FEN1
Agencies
[Federal Register Volume 78, Number 37 (Monday, February 25, 2013)]
[Notices]
[Pages 12769-12770]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-04210]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Vaccine Research Center Board of Scientific Counselors, NIAID.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute of Allergy and Infectious Diseases, including consideration
of personnel qualifications and performance, and the competence of
individual investigators, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one form
of identification (for example, a government-issued photo ID, driver's
license, or passport) and to state the purpose of their visit.
Name of Committee: Vaccine Research Center Board of Scientific
Counselors, NIAID.
Date: April 29-30, 2013.
Closed: 8:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 40, Room 1201/
1203, 40 Center Drive, Bethesda, MD 20892.
Contact Person: John R Mascola, MD, Deputy Director, Vaccine
Research Center, NIAID, NIH, 40 Convent Drive, Bethesda, MD 20892,
(301) 496-1852, jmascola@nih.gov.
Name of Committee: Vaccine Research Center Board of Scientific
Counselors, NIAID.
Date: April 29, 2013.
Closed: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate personal qualifications and
performances, and competence of individual investigators.
Place: National Institutes of Health, Building 40, Room 1201/
1203, 40 Center Drive, Bethesda, MD 20892.
Contact Person: John R. Mascola, MD, Deputy Director, Vaccine
Research Center, NIAID, NIH, 40 Convent Drive, Bethesda, MD 20892,
(301) 496-1852, jmascola@nih.gov.
Name of Committee: Vaccine Research Center Board of Scientific
Counselors, NIAID.
Date: April 30, 2013.
[[Page 12770]]
Closed: 8:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate personal qualifications and
performances, and competence of individual investigators.
Place: National Institutes of Health, Building 40, Room 1201/
1203, 40 Center Drive, Bethesda, MD 20892, (301) 496-1852.
Contact Person: John R. Mascola, MD, Deputy Director, Vaccine
Research Center, NIAID, NIH, 40 Convent Drive, Bethesda, MD 20892,
(301) 496-1852, jmascola@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: February 19, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-04210 Filed 2-22-13; 8:45 am]
BILLING CODE 4140-01-P